stockrow
Saturday 7 November 2026
Export HUMA’s income statement to Excel — free account
Humacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022.
- Revenue
- +34.9%
- EPS
- +33.3%
- Free cash flow
- +17.9%
- Total debt
- +437.5%
Quarter to June 2026, against a year earlier
0.44
0.04
+10.00%
Follow HUMA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | 1 | 2 | — | — | 2 | 2 | +6.4% | 4 | 22 | 111 | +279.1% | |
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | — | — | (376.05) | (494.58) | (476.1) pt | ||||||
| EBT | — | — | — | — | (67) | (26) | (12) | (111) | (149) | (41) | (97) | (9.3%) | ||||||
| EBT margin, % | — | — | — | — | (4,461.70) | (2,096.36) | (764.54) | 0.00 | 0.00 | (2,003.58) | (4,560.82) | +2,458.1 pt | ||||||
| Net income | — | 0 | — | 0 | (67) | (26) | (12) | (111) | (149) | (41) | (97) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.26 | 0.03 | 0.02 | 0.00 | 0.00 | 0.01 | 0.01 | (45.1%) | |||||
| Earnings | — | — | — | — | (11.54) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) | (0.49) | (53.2%) | ||||||
| Cash flow | — | — | — | — | (9.64) | (2.03) | (0.69) | (0.71) | (0.83) | (0.66) | (0.41) | (41.4%) | ||||||
| Capex | — | — | — | — | (0.05) | (0.01) | (0.01) | (0.02) | (0.01) | (0.01) | 0.00 | (34.5%) | ||||||
| Free cash flow | — | — | — | — | (9.68) | (2.04) | (0.70) | (0.73) | (0.84) | (0.67) | (0.42) | (41.4%) | ||||||
| Book value | — | — | — | — | (60.76) | 3.06 | 1.13 | 0.13 | (0.44) | 0.02 | 0.13 | n/m | ||||||
| Shares, m | — | — | — | — | 6 | 40 | 103 | 103 | 118 | 158 | 187 | +93.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 229.44 | 138.94 | — | — | 74.50 | 48.58 | 110.7 | ||||||
| P/B | — | — | — | — | 1.13 | 2.37 | 1.86 | — | — | 48.84 | 3.30 | 13.6 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 89.28 | 66.94 | — | — | 80.36 | 41.40 | 59.1 | ||||||
| EV/FCF | — | — | — | — | 0.00 | (1.39) | (1.45) | — | — | (1.55) | (0.90) | (1.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (56) | (81) | (71) | (73) | (98) | (105) | (97) | +13.6% | |||||
| Capex | — | — | — | — | 0 | 0 | (1) | (2) | (2) | (1) | 0 | +27.0% | ||||||
| Free cash flow | — | — | — | — | (56) | (81) | (72) | (76) | (100) | (106) | (98) | +13.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 30 | 218 | 135 | 65 | 28 | 49 | 78 | +10.3% | |||||
| Net debt | — | — | — | — | (17) | (177) | (113) | (64) | (31) | 12 | (15) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | (350) | 122 | 117 | 14 | (53) | 3 | 31 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (124.71) | (13.47) | (4.88) | (66.63) | (111.77) | (32.12) | (68.16) | (32.1) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (1,247.32) | 0.00 | 0.00 | (449.67) | (433.66) | (449.7) pt | ||||||
| ROE | — | — | — | — | 58.32 | 23.21 | (10.01) | (169.81) | 760.17 | 164.78 | (534.42) | +106.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 146 | 164 | 185 | 220 | 184 | — | +112.5% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.75 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Humacyte, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics Inc. | $113.1M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| ENGN enGene Therapeutics Inc | $112.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| NKTX Nkarta, Inc. | $112.5M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CDXS Codexis, Inc. | $111.7M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $111.5M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| HUMA Humacyte, Inc. | $109.9M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | |
| NERV Minerva Neurosciences, Inc | $109.8M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OTLK Outlook Therapeutics, Inc. | $106.9M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| VYGR Voyager Therapeutics, Inc. | $106.0M | — (loss-making) | — (loss-making) | −69.97% (below 0%: shrinking) | n/m | +37.08% (above 0%: growing) | 100.00% | (658.25%) | Compare |
| Median of peers | $111.6M | — | — | −2.69% | — | −1.55% | 76.45% | (65.03%) |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 5.23m | (725.03k) | 33.80 |
| 2024 | 905.44k | 2.90m | 177.82 |
Ownership
Directors and executive officers, together
3.10%
Fresenius Medical Care Holdings, Inc.
8.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement